uniQure reports early data from AMT-260 epilepsy gene therapy trial

June 19, 2026 7:05 AM

uniQure N.V. (NASDAQ: QURE) released preliminary six-month data from the first cohort of its Phase I/IIa clinical trial of AMT-260 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found